Project Grant R01ES024434

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to enhance the efficacy of immunotherapy against metastatic colorectal cancer (MCRC). The $640,583 grant awarded to Cold Spring Harbor Laboratory will fund research to activate the PPARD-CPT1A axis in CD8+ T cells, which is expected to boost the fitness and anti-tumor activity of these immune cells within the MCRC tumor microenvironment. The 5-year project will delineate the underlying...

This federal Cooperative Agreement award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $257,709 to the University of California, Los Angeles (UCLA) to investigate the impact of dietary lipids on the initiation and progression of pancreatic ductal adenocarcinoma (PDA). The research project has two main aims: 1) Examine the effects of a high-fat diet comprised of lard (HFLD), which contains mostly saturated long-chain fatty acids, on PDA tumorigenesis using...

The National Cancer Institute (NCI) awarded a 5-year, $767,324 Cooperative Agreement (CFDA 93.396 - Cancer Biology Research) to the Van Andel Research Institute (VAI) to investigate how dietary regulation, specifically caloric restriction, impacts anti-tumor immunity through its effects on CD8 T cell metabolism and fate in the tumor microenvironment. The study aims to determine the mechanisms by which caloric restriction boosts CD8 T cell-mediated anti-tumor immunity, enhancing the function of...

This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $496,391 to the University of North Carolina at Chapel Hill to conduct research on manipulating lipid metabolism to reverse immune dysfunction in solid cancers. The research aims to understand how the tumor microenvironment impairs the metabolism of tumor-infiltrating lymphocytes (TILs), reducing their ability to effectively fight cancer. Specifically, the project will investigate how the...

This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) is focused on advancing research to elucidate the underlying processes of failed resolution of inflammation initiated by environmental chemicals and their link to cancer development. The $749,474 grant awarded to Beth Israel Deaconess Medical Center, Inc. aims to: Profile lipid autacoid mediators, including eicosanoids and specialized pro-resolving mediators (SPMs), as well as cytokines to test...

This Cooperative Agreement award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) provides funding of $179,988 to the University of Utah to conduct research on the role of dietary lipids in accelerating breast cancer tumor growth, particularly in the context of obesity. The key objectives are to: Determine if breast cancer cells preferentially utilize dietary lipids over glucose in lipid-rich environments, such as those found in obesity. Trace the metabolic fate of...

This $159,183 Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports research investigating the role of diet and the ACSS2 enzyme in the metabolic and epigenetic regulation of colorectal cancer. The primary objectives are to determine how the dietary components acetate and fructose interact to affect colorectal cancer growth and acetyl-CoA metabolism, as well as identify the mechanisms by which acetate, fructose, and ACSS2 regulate...

The National Cancer Institute (CFDA 93.396 - Cancer Biology Research) awarded Loyola University of Chicago a $461,844 project grant titled "Hyperpolarized 13C Metabolic Imaging of Tumorigenesis in the Liver". The objective is to use novel hyperpolarized 13C probes to image glycolysis, a critical pathway in hepatocellular carcinoma (HCC) development, and establish in vivo imaging biomarkers to assess altered liver metabolism during HCC progression. The project aims to synthesize a...

This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), provides $551,848 to the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, MA to investigate the molecular mechanisms by which the transcription factor SOX9 impairs cell differentiation and drives developmental reprogramming in colorectal cancer (CRC). The research aims to: 1) Use single-cell sequencing analyses to identify regulators of fetal gene...

This Cooperative Agreement award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) provides $624,518 in funding to the University of South Florida to conduct research on the role of arachidonic acid metabolism in modulating the tumor immune microenvironment for colorectal cancer. The project aims to: 1) analyze arachidonic acid pathway lipid mediators in a large reference set of clinically-curated colorectal cancer samples to understand their relationship to immune...